About Ciromed
We develop innovative approaches for the treatment of dry age-related macular degeneration.
Our Mission
We research and develop non-invasive therapeutic approaches for patients with dry age-related macular degeneration. Our goal is to contribute to improving the care situation through scientifically founded research.
Through clinical studies and close collaboration with leading research institutions, we work on innovative technologies for ophthalmic care.
Our Vision
We are working toward a future where patients with dry AMD have access to effective, non-invasive therapy options. With the MACULIGHT® device, we are researching a promising approach for home use.
We are convinced that photobiomodulation holds significant potential for AMD research, and we aim to further validate this approach through clinical evidence.
Our History
Founding of Ciromed GmbH
Founded with the goal of researching and making photobiomodulation technology accessible for AMD patients.
First Prototype Development
Development of the first MACULIGHT® prototype in collaboration with the Technical University of Cologne.
Start of the MACULIGHT Study
Beginning of the BMFTR-funded multicenter clinical study at German eye clinics.
Ongoing Clinical Testing
The clinical study continues. Initial results are expected in the coming months.
Our Values
Scientific Rigor
All statements are based on clinical evidence and peer-reviewed research.
Quality
Highest standards in research, development, and patient safety.
Responsibility
Transparent communication about the possibilities and limitations of our technology.
Patient Focus
The needs and safety of patients are at the center of everything we do.